Business Context and Reporting Period
Company: Oncolytics Biotech Inc.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Date: November 18, 2009 (Warrant Indenture Date); Filed November 25, 2009
Context: This filing incorporates by reference a Warrant Indenture dated November 18, 2009, between Oncolytics Biotech Inc. and Computershare Trust Company of Canada. The filing relates to a capital raise involving the issuance of Units, each consisting of one Common Share and 0.4 of one Warrant.
Key Financial Metrics and Capital Structure
The filing does not contain audited financial statements, revenue, profit, or cash flow data. It details the terms of a specific financing transaction:
- Units Issued: 4,250,000 Units (1 Common Share + 0.4 Warrant per Unit) issued at no additional cost to the holder (implied as part of a broader offering).
- Over-Allotment Option: Underwriters (Oppenheimer & Co. Inc. and Canaccord Capital Corporation) granted an option to purchase up to 637,500 additional Common Shares at U.S.$2.95 and up to 255,000 additional Warrants at U.S.$0.05 per 0.4 Warrant.
- Total Warrants Authorized: Up to 1,955,000 Warrants (including over-allotment).
- Exercise Price: U.S.$3.50 per Common Share.
- Expiry Date: November 23, 2014.
- Accelerated Exercise Trigger: If the 10-day volume-weighted average trading price exceeds the Canadian dollar equivalent of U.S.$6.50, the company may accelerate expiry to 30 days after notice.
Material Changes and Transaction Details
This filing represents a material change in the company's capital structure through the creation of new equity instruments. Key terms include:
- Closing Date: November 23, 2009 (or later as agreed).
- Underwriters: Oppenheimer & Co. Inc. and Canaccord Capital Corporation.
- Trustee: Computershare Trust Company of Canada.
- Adjustments: The number of shares and exercise price are subject to adjustment for stock splits, dividends, reorganizations, or rights offerings priced below 80% of the current market price.
- Cashless Exercise: U.S. Persons may exercise warrants on a cashless basis if a U.S. Registration Statement is not effective.
Guidance, Risks, and Contingencies
Management Commentary: The filing is a legal instrument and does not contain forward-looking guidance or management commentary regarding operational performance.
Risks and Contingencies:
- U.S. Registration Risk: Warrants held by U.S. Persons cannot be exercised for cash if a U.S. Registration Statement is not effective; they must be exercised on a cashless basis.
- Dilution: The issuance of shares upon warrant exercise will dilute existing shareholders.
- Acceleration Risk: The company retains the sole discretion to accelerate the expiry date if the share price exceeds U.S.$6.50, potentially limiting the upside for warrant holders.
- Legal Jurisdiction: The Indenture is governed by the laws of the Province of Alberta, Canada.
Investor Verification Checklist
- Verify the effectiveness of the U.S. Registration Statement (Form F-10, File No. 333-151513) to determine if U.S. holders can exercise warrants for cash.
- Confirm the final number of Units and Warrants issued after the exercise of the Over-Allotment Option.
- Monitor the 10-day volume-weighted average trading price to assess the risk of accelerated expiry (triggered at U.S.$6.50 equivalent).
- Review the company's subsequent filings for any adjustments to the exercise price or number of shares due to corporate actions (splits, dividends, etc.).
- Check the status of the company's listing on the Toronto Stock Exchange (TSX) as required by the Indenture covenants.